Skip to content
  • (312) 598-2610
  • info@ipfdalaw.com
  • 109 Symonds Drive, #174, Hinsdale, IL 60522-0174
Untitled design (7)
  • About
    • Detailed Description
    • Our Team
    • Fee Structures
  • Services
    • Patent Litigation
    • Commercial Litigation
    • False Advertising & Unfair Competition
    • Generic Drugs
    • Branded Drugs and 505(b)(2)
    • Medical Devices
    • FDA/Exclusivity/GMP
    • Contracts & Licensing
    • Government Investigations
  • News
  • Videos
  • Recent Cases
  • Contact Us
  • About
    • Detailed Description
    • Our Team
    • Fee Structures
  • Services
    • Patent Litigation
    • Commercial Litigation
    • False Advertising & Unfair Competition
    • Generic Drugs
    • Branded Drugs and 505(b)(2)
    • Medical Devices
    • FDA/Exclusivity/GMP
    • Contracts & Licensing
    • Government Investigations
  • News
  • Videos
  • Recent Cases
  • Contact Us
中文

Author: Christopher Bruno

The Patent Eligibility Restoration Act: Revisions to Section 101 Moving Closer to the Finish Line

The Subcommittee on Intellectual Property of the Senate Judiciary Committee recently took another step towards moving forward with a redefinition of patent-eligible subject matter under Section 101 of the Patent Act when it held a hearing to consider the Patent Eligibility Restoration Act of 2025 (PERA), introduced on a bipartisan basis by Senators Coons (D-DE) […]

Patents
Hatch-Waxman Litigation
Trade Secrets
Antitrust/Unfair Competition
FDA Counseling
Branded/Generic/ 505(b)(2)
Life Cycles
Contracts Licensing
Freedom to Operate

Quick Contact

Address

  • 109 Symonds Drive, #174, Hinsdale, IL 60522-0174
  • (312) 598-2610
  • info@ipfdalaw.com

Ⓒ 2021 - IPFDA law All Rights Are Reserved